Mettler-Toledo International Inc.
MTD Healthcare Medical - Diagnostics & Research NYSE
$1209.65
$-51.56 (-4.09%)
Open: $1242.90 | High: $1243.09 | Low: $1209.62 | Prev Close: $1261.21
Market Cap: $24.71B
Volume: 133K | Avg: 145K
Last updated: March 09, 2026 at 02:03 AMInvestment Rating
Sell
Overall Score: 40/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 532
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 30.03 |
| P/B Ratio | -1043.04 |
| P/S Ratio | 6.14 |
| EPS | $40.28 |
| Beta | 1.44 |
| Shares Outstanding | 20.43M |
| 52-Week High | $1525.17 |
| 52-Week Low | $946.69 |
| SMA 50 | $1398.93 |
| SMA 200 | $1318.82 |
| Next Earnings | April 30, 2026 09:00 PM ET |
Financial Ratios
| Gross Margin | 57.5% |
| Operating Margin | 27.8% |
| Net Margin | 21.6% |
| ROE | -487.2% |
| ROA | 23.4% |
| Debt/Equity | -99.14 |
| Current Ratio | 1.14 |
| Quick Ratio | 0.81 |
Balance Sheet
| Total Assets | $3.71B |
| Total Liabilities | $3.74B |
| Total Equity | $-23,636,000 |
|
|
|
| Cash | $66.89M |
| Total Debt | $2.34B |
| Net Debt | $2.28B |
Income Statement
| Revenue | $4.03B |
| Gross Profit | $2.32B |
| Operating Income | $1.12B |
| Net Income | $869.19M |
|
|
|
| EBITDA | $1.23B |
| Revenue/Share | $197.56 |
Cash Flow
| Operating CF | $955.77M |
| CapEx | $107.12M |
| Free Cash Flow | $848.65M |
|
|
|
| Book Value/Share | $-1.16 |
| Tangible Book/Share | $-51.12 |
| Equity/Share | $-1.16 |
Technical Indicators
| RSI (14) | 27.92 Oversold |
| MACD |
-31.28
Signal: -20.27
|
| Volatility | 27.33% |
| Trading Signal | Oversold |
Performance & Returns
| 1 Year | +4.36% |
| Sharpe Ratio | 0.17 Fair |
| Volatility (Ann.) | 27.73% Moderate |
| MTD (1Y) | +4.36% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -8.67% |
Sector Comparison (Healthcare)
| Metric | MTD | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 30.03 | 27.61 | 62% |
| P/B Ratio | -1043.04 | 0.54 | 0% |
| ROE (%) | -487.21% | 0.08% | 0% |
| Net Margin (%) | 21.59% | 9.08% | 79% |
| Stock Score | 532 | 544.0 | 34% |
| 1Y Return (%) | +4.36 % | +8.22 % | 50% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MTD | $1209.65 | $1293.33 | $1320.60 | $1343.41 | $1399.67 | $1319.01 | 27.92 | -31.28 | 27.33% | 34379 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the MTD stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| MTD | Dimensional Fund Advisors LP Sells 5,160 Shares of Mettler-Toledo International, Inc. $MTD | Neutral | defenseworld.net | Read More |
| MTD | Bell Asset Management Ltd Decreases Holdings in Mettler-Toledo International, Inc. $MTD | Negative | defenseworld.net | Read More |
| MTD | After Plunging 7.4% in 4 Weeks, Here's Why the Trend Might Reverse for Mettler-Toledo (MTD) | Neutral | zacks.com | Read More |
| MTD | Baron Growth Fund Q4 2025 Contributors And Detractors | Positive | seekingalpha.com | Read More |
| MTD | Buy 5 Non-Tech Wide Moat Stocks to Enhance Your Portfolio Returns | Neutral | zacks.com | Read More |
Recent Insider Trading
No recent insider trading data available for MTD
Company Information
Mettler-Toledo International Inc. engages in the manufacture and supply of precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company's laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments. Its industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detection, x-ray, checkweighing, camera-based imaging equipment, track-and-trace solutions, and product inspection systems. The company's retail weighing solutions consist of networked scales and software, stand-alone scales, and automated packaging and labeling solutions for handling fresh goods. It serves the life science industry, independent research organizations, and testing labs; food and beverage manufacturers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.
| CEO | Patrick K. Kaltenbach |
| Employees | 16000 |
| Country | US |
| IPO Date | 1997-11-14 |
| Exchange | NYSE |
| Website | https://www.mt.com |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
Similar Stocks (Healthcare - Medical - Diagnostics & Research)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category